Vivet Therapeutics Announces Presentations at Upcoming European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress
23 oct. 2023 07h30 HE
|
Vivet Therapeutics
Vivet Therapeutics Announces Presentations at Upcoming European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress Paris, France, October 23, 2023 (GLOBE NEWSWIRE) – Vivet Therapeutics...
VTX-801 Receives U.S. FDA Fast Track Designation for the Treatment of Wilson Disease
12 août 2021 07h00 HE
|
Vivet Therapeutics
VTX-801 Receives U.S. FDA Fast Track Designation for the Treatment of Wilson Disease Paris, France and New York, NY, August 12, 2021 – Vivet Therapeutics (“Vivet”), a clinical-stage...
Vivet Therapeutics Announces Multiple Projects Update, Including New VTX-803 Preclinical data To Be Presented At 2021 American Society Of Gene And Cell Therapy Annual Meeting
10 mai 2021 10h00 HE
|
Vivet Therapeutics
Vivet Therapeutics Announces Multiple Projects Update, Including New VTX-803 Preclinical data To Be Presented At 2021 American Society Of Gene And Cell Therapy Annual Meeting Compelling...
Vivet Therapeutics y Pfizer Inc reciben autorización de la FDA para iniciar GATEWAY, ensayo clínico de fase 1/2 con VTX-801, la terapia génica de Vivet para la enfermedad de Wilson
18 nov. 2020 01h00 HE
|
Vivet Therapeutics
Vivet Therapeutics y Pfizer Inc reciben...
Vivet Therapeutics and Pfizer Inc. Announce FDA Authorization to Proceed with GATEWAY, the Phase 1/2 Study for VTX-801, Vivet’s Investigational Gene Therapy for Wilson Disease
18 nov. 2020 01h00 HE
|
Vivet Therapeutics
Vivet Therapeutics and Pfizer...